A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Inclusion Criteria:

- Eligible for continuing atezolizumab-based therapy at the time of roll-over from the
parent study, as per the parent study protocol or

- Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored
study as per the parent study protocol, with no access to commercially available
comparator agent

- Time between the last dose of treatment received in parent study and first dose in
extension study is no longer than the interruption period allowed in the parent study.
First dose of study treatment in this extension study will be received within 7 days
of the treatment interruption window allowed by the parent study

- Continue to benefit from atezolizumab-based study treatment or from the comparator at
the time of roll-over from the parent study as assessed by the investigator

- Negative serum pregnancy test within 7 days prior to start of study treatment in women
of childbearing potential

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive methods, and agreement to refrain from donating eggs

- For men: agreement to remain abstinent or use contraceptive measures, and agreement to
refrain from donating sperm

Exclusion Criteria:

- Meet any of the study treatment discontinuation criteria specified in the parent study
at the time of enrollment in this extension study

- Study treatment or comparator agent is commercially marketed in the patient's country
for the patient-specific disease and is accessible to the patient

- Permanent discontinuation of atezolizumab for any reason during the parent study or
during the time between last treatment in the parent study and the first dose of study
treatment in this extension study (if applicable)

- Ongoing serious adverse event(s) that has not resolved to baseline level or Grade ≤1
from the parent study or during the time between the last treatment in the parent
study and the first dose of study treatment in this extension study

- Any condition that, in the opinion of the investigator, would interfere with the
interpretation of patient safety or place the patient at high risk for
treatment-related complications

- Concurrent participation in any therapeutic clinical trial (other than the parent
study)

- Pregnant or lactating, or intending to become pregnant during this extension study and
for the period after the last dose of study treatment specified in the designated
referenced safety information (RSI)